nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—SELE—atherosclerosis	0.239	0.439	CbGaD
Carvedilol—VCAM1—atherosclerosis	0.228	0.419	CbGaD
Carvedilol—VEGFA—atherosclerosis	0.0769	0.141	CbGaD
Carvedilol—CYP2D6—Niacin—atherosclerosis	0.0144	0.0783	CbGbCtD
Carvedilol—CYP2C9—Rosuvastatin—atherosclerosis	0.0134	0.0728	CbGbCtD
Carvedilol—ABCB1—Ezetimibe—atherosclerosis	0.013	0.0706	CbGbCtD
Carvedilol—CYP2C9—Simvastatin—atherosclerosis	0.0124	0.0677	CbGbCtD
Carvedilol—CYP2C9—Pravastatin—atherosclerosis	0.0122	0.0662	CbGbCtD
Carvedilol—CYP2C9—Lovastatin—atherosclerosis	0.0122	0.0662	CbGbCtD
Carvedilol—ABCB1—Simvastatin—atherosclerosis	0.0121	0.0657	CbGbCtD
Carvedilol—ABCB1—Pravastatin—atherosclerosis	0.0118	0.0643	CbGbCtD
Carvedilol—ABCB1—Lovastatin—atherosclerosis	0.0118	0.0643	CbGbCtD
Carvedilol—CYP2D6—Simvastatin—atherosclerosis	0.0114	0.0619	CbGbCtD
Carvedilol—CYP2D6—Pravastatin—atherosclerosis	0.0111	0.0606	CbGbCtD
Carvedilol—CYP2D6—Lovastatin—atherosclerosis	0.0111	0.0606	CbGbCtD
Carvedilol—CYP3A4—Ezetimibe—atherosclerosis	0.00777	0.0423	CbGbCtD
Carvedilol—CYP3A4—Rosuvastatin—atherosclerosis	0.00777	0.0423	CbGbCtD
Carvedilol—CYP3A4—Simvastatin—atherosclerosis	0.00723	0.0393	CbGbCtD
Carvedilol—CYP3A4—Pravastatin—atherosclerosis	0.00707	0.0385	CbGbCtD
Carvedilol—CYP3A4—Lovastatin—atherosclerosis	0.00707	0.0385	CbGbCtD
Carvedilol—VCAM1—tunica intima—atherosclerosis	0.00579	0.0837	CbGeAlD
Carvedilol—SELE—vein—atherosclerosis	0.00529	0.0764	CbGeAlD
Carvedilol—VCAM1—vein—atherosclerosis	0.00486	0.0703	CbGeAlD
Carvedilol—SELE—umbilical vein—atherosclerosis	0.00384	0.0555	CbGeAlD
Carvedilol—VCAM1—umbilical vein—atherosclerosis	0.00353	0.051	CbGeAlD
Carvedilol—NPPB—artery—atherosclerosis	0.00319	0.0461	CbGeAlD
Carvedilol—NPPB—blood vessel—atherosclerosis	0.00248	0.0359	CbGeAlD
Carvedilol—SELE—artery—atherosclerosis	0.00215	0.0311	CbGeAlD
Carvedilol—VCAM1—artery—atherosclerosis	0.00198	0.0286	CbGeAlD
Carvedilol—HIF1A—artery—atherosclerosis	0.00191	0.0276	CbGeAlD
Carvedilol—GJA1—artery—atherosclerosis	0.00185	0.0267	CbGeAlD
Carvedilol—SELE—endothelium—atherosclerosis	0.00182	0.0263	CbGeAlD
Carvedilol—SELE—blood vessel—atherosclerosis	0.00168	0.0243	CbGeAlD
Carvedilol—VCAM1—endothelium—atherosclerosis	0.00167	0.0242	CbGeAlD
Carvedilol—HIF1A—endothelium—atherosclerosis	0.00161	0.0233	CbGeAlD
Carvedilol—GJA1—endothelium—atherosclerosis	0.00156	0.0226	CbGeAlD
Carvedilol—VCAM1—blood vessel—atherosclerosis	0.00154	0.0223	CbGeAlD
Carvedilol—HIF1A—blood vessel—atherosclerosis	0.00148	0.0215	CbGeAlD
Carvedilol—GJA1—blood vessel—atherosclerosis	0.00144	0.0208	CbGeAlD
Carvedilol—NPPB—cardiovascular system—atherosclerosis	0.00111	0.016	CbGeAlD
Carvedilol—SELE—connective tissue—atherosclerosis	0.00086	0.0124	CbGeAlD
Carvedilol—VCAM1—connective tissue—atherosclerosis	0.000791	0.0114	CbGeAlD
Carvedilol—HIF1A—connective tissue—atherosclerosis	0.000761	0.011	CbGeAlD
Carvedilol—SELE—cardiovascular system—atherosclerosis	0.000748	0.0108	CbGeAlD
Carvedilol—GJA1—connective tissue—atherosclerosis	0.000738	0.0107	CbGeAlD
Carvedilol—VCAM1—cardiovascular system—atherosclerosis	0.000688	0.00995	CbGeAlD
Carvedilol—ADRB3—connective tissue—atherosclerosis	0.000677	0.00979	CbGeAlD
Carvedilol—HIF1A—cardiovascular system—atherosclerosis	0.000662	0.00958	CbGeAlD
Carvedilol—SELE—adipose tissue—atherosclerosis	0.00066	0.00954	CbGeAlD
Carvedilol—GJA1—cardiovascular system—atherosclerosis	0.000642	0.00929	CbGeAlD
Carvedilol—VCAM1—adipose tissue—atherosclerosis	0.000607	0.00878	CbGeAlD
Carvedilol—HIF1A—adipose tissue—atherosclerosis	0.000584	0.00845	CbGeAlD
Carvedilol—GJA1—adipose tissue—atherosclerosis	0.000567	0.00819	CbGeAlD
Carvedilol—NDUFC2—cardiovascular system—atherosclerosis	0.000559	0.00809	CbGeAlD
Carvedilol—ADRB3—adipose tissue—atherosclerosis	0.000519	0.00751	CbGeAlD
Carvedilol—NDUFC2—adipose tissue—atherosclerosis	0.000493	0.00713	CbGeAlD
Carvedilol—SELE—liver—atherosclerosis	0.000463	0.00669	CbGeAlD
Carvedilol—VEGFA—adipose tissue—atherosclerosis	0.000447	0.00647	CbGeAlD
Carvedilol—VCAM1—liver—atherosclerosis	0.000426	0.00616	CbGeAlD
Carvedilol—HIF1A—liver—atherosclerosis	0.00041	0.00592	CbGeAlD
Carvedilol—GJA1—liver—atherosclerosis	0.000397	0.00575	CbGeAlD
Carvedilol—PTGS1—artery—atherosclerosis	0.000392	0.00568	CbGeAlD
Carvedilol—NDUFC2—liver—atherosclerosis	0.000346	0.005	CbGeAlD
Carvedilol—PTGS1—endothelium—atherosclerosis	0.000332	0.00479	CbGeAlD
Carvedilol—VEGFA—liver—atherosclerosis	0.000314	0.00454	CbGeAlD
Carvedilol—PTGS1—blood vessel—atherosclerosis	0.000306	0.00442	CbGeAlD
Carvedilol—XDH—liver—atherosclerosis	0.000279	0.00404	CbGeAlD
Carvedilol—ADRB1—connective tissue—atherosclerosis	0.000277	0.004	CbGeAlD
Carvedilol—ADRB1—cardiovascular system—atherosclerosis	0.000241	0.00348	CbGeAlD
Carvedilol—ADRB1—adipose tissue—atherosclerosis	0.000212	0.00307	CbGeAlD
Carvedilol—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000202	0.0021	CcSEcCtD
Carvedilol—Vision blurred—Lovastatin—atherosclerosis	0.000202	0.0021	CcSEcCtD
Carvedilol—Visual impairment—Pravastatin—atherosclerosis	0.0002	0.00208	CcSEcCtD
Carvedilol—Ill-defined disorder—Lovastatin—atherosclerosis	0.000199	0.00207	CcSEcCtD
Carvedilol—Flatulence—Simvastatin—atherosclerosis	0.000197	0.00205	CcSEcCtD
Carvedilol—Tinnitus—Niacin—atherosclerosis	0.000197	0.00205	CcSEcCtD
Carvedilol—Erythema multiforme—Pravastatin—atherosclerosis	0.000197	0.00205	CcSEcCtD
Carvedilol—Angioedema—Lovastatin—atherosclerosis	0.000196	0.00204	CcSEcCtD
Carvedilol—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000195	0.00203	CcSEcCtD
Carvedilol—Anaemia—Ezetimibe—atherosclerosis	0.000194	0.00202	CcSEcCtD
Carvedilol—Tinnitus—Pravastatin—atherosclerosis	0.000194	0.00202	CcSEcCtD
Carvedilol—Malaise—Lovastatin—atherosclerosis	0.000193	0.00201	CcSEcCtD
Carvedilol—Muscle spasms—Simvastatin—atherosclerosis	0.000192	0.002	CcSEcCtD
Carvedilol—Vertigo—Lovastatin—atherosclerosis	0.000192	0.002	CcSEcCtD
Carvedilol—Angioedema—Ezetimibe—atherosclerosis	0.000192	0.002	CcSEcCtD
Carvedilol—Angiopathy—Niacin—atherosclerosis	0.000192	0.00199	CcSEcCtD
Carvedilol—Leukopenia—Lovastatin—atherosclerosis	0.000192	0.00199	CcSEcCtD
Carvedilol—ADRA1A—cardiovascular system—atherosclerosis	0.00019	0.00275	CbGeAlD
Carvedilol—Malaise—Ezetimibe—atherosclerosis	0.000189	0.00197	CcSEcCtD
Carvedilol—Vision blurred—Simvastatin—atherosclerosis	0.000189	0.00196	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000188	0.00195	CcSEcCtD
Carvedilol—Alopecia—Niacin—atherosclerosis	0.000187	0.00194	CcSEcCtD
Carvedilol—Insomnia—Rosuvastatin—atherosclerosis	0.000186	0.00194	CcSEcCtD
Carvedilol—Ill-defined disorder—Simvastatin—atherosclerosis	0.000186	0.00193	CcSEcCtD
Carvedilol—Palpitations—Ezetimibe—atherosclerosis	0.000185	0.00193	CcSEcCtD
Carvedilol—Paraesthesia—Rosuvastatin—atherosclerosis	0.000185	0.00193	CcSEcCtD
Carvedilol—Anaemia—Simvastatin—atherosclerosis	0.000185	0.00193	CcSEcCtD
Carvedilol—KCNH2—cardiovascular system—atherosclerosis	0.000184	0.00266	CbGeAlD
Carvedilol—Malnutrition—Niacin—atherosclerosis	0.000184	0.00191	CcSEcCtD
Carvedilol—Alopecia—Pravastatin—atherosclerosis	0.000184	0.00191	CcSEcCtD
Carvedilol—Cough—Ezetimibe—atherosclerosis	0.000183	0.00191	CcSEcCtD
Carvedilol—Angioedema—Simvastatin—atherosclerosis	0.000183	0.0019	CcSEcCtD
Carvedilol—Myalgia—Lovastatin—atherosclerosis	0.000182	0.0019	CcSEcCtD
Carvedilol—Chest pain—Lovastatin—atherosclerosis	0.000182	0.0019	CcSEcCtD
Carvedilol—Arthralgia—Lovastatin—atherosclerosis	0.000182	0.0019	CcSEcCtD
Carvedilol—Dyspepsia—Rosuvastatin—atherosclerosis	0.000181	0.00189	CcSEcCtD
Carvedilol—Hypertension—Ezetimibe—atherosclerosis	0.000181	0.00189	CcSEcCtD
Carvedilol—Flatulence—Niacin—atherosclerosis	0.000181	0.00188	CcSEcCtD
Carvedilol—ABCB1—blood vessel—atherosclerosis	0.000181	0.00261	CbGeAlD
Carvedilol—Malaise—Simvastatin—atherosclerosis	0.00018	0.00188	CcSEcCtD
Carvedilol—Tension—Niacin—atherosclerosis	0.00018	0.00188	CcSEcCtD
Carvedilol—Discomfort—Lovastatin—atherosclerosis	0.00018	0.00187	CcSEcCtD
Carvedilol—Vertigo—Simvastatin—atherosclerosis	0.00018	0.00187	CcSEcCtD
Carvedilol—Leukopenia—Simvastatin—atherosclerosis	0.000179	0.00186	CcSEcCtD
Carvedilol—Myalgia—Ezetimibe—atherosclerosis	0.000179	0.00186	CcSEcCtD
Carvedilol—Chest pain—Ezetimibe—atherosclerosis	0.000179	0.00186	CcSEcCtD
Carvedilol—Arthralgia—Ezetimibe—atherosclerosis	0.000179	0.00186	CcSEcCtD
Carvedilol—Nervousness—Niacin—atherosclerosis	0.000178	0.00186	CcSEcCtD
Carvedilol—Flatulence—Pravastatin—atherosclerosis	0.000178	0.00186	CcSEcCtD
Carvedilol—Dry mouth—Lovastatin—atherosclerosis	0.000178	0.00185	CcSEcCtD
Carvedilol—Tension—Pravastatin—atherosclerosis	0.000178	0.00185	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000177	0.00185	CcSEcCtD
Carvedilol—Muscle spasms—Niacin—atherosclerosis	0.000177	0.00184	CcSEcCtD
Carvedilol—Discomfort—Ezetimibe—atherosclerosis	0.000177	0.00184	CcSEcCtD
Carvedilol—Constipation—Rosuvastatin—atherosclerosis	0.000176	0.00183	CcSEcCtD
Carvedilol—Pain—Rosuvastatin—atherosclerosis	0.000176	0.00183	CcSEcCtD
Carvedilol—Confusional state—Lovastatin—atherosclerosis	0.000176	0.00183	CcSEcCtD
Carvedilol—Nervousness—Pravastatin—atherosclerosis	0.000176	0.00183	CcSEcCtD
Carvedilol—Dry mouth—Ezetimibe—atherosclerosis	0.000175	0.00182	CcSEcCtD
Carvedilol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000175	0.00182	CcSEcCtD
Carvedilol—Muscle spasms—Pravastatin—atherosclerosis	0.000174	0.00181	CcSEcCtD
Carvedilol—Infection—Lovastatin—atherosclerosis	0.000173	0.00181	CcSEcCtD
Carvedilol—Vision blurred—Niacin—atherosclerosis	0.000173	0.0018	CcSEcCtD
Carvedilol—Confusional state—Ezetimibe—atherosclerosis	0.000173	0.0018	CcSEcCtD
Carvedilol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000171	0.00178	CcSEcCtD
Carvedilol—Thrombocytopenia—Lovastatin—atherosclerosis	0.000171	0.00178	CcSEcCtD
Carvedilol—Vision blurred—Pravastatin—atherosclerosis	0.000171	0.00177	CcSEcCtD
Carvedilol—Chest pain—Simvastatin—atherosclerosis	0.00017	0.00177	CcSEcCtD
Carvedilol—Arthralgia—Simvastatin—atherosclerosis	0.00017	0.00177	CcSEcCtD
Carvedilol—Myalgia—Simvastatin—atherosclerosis	0.00017	0.00177	CcSEcCtD
Carvedilol—Infection—Ezetimibe—atherosclerosis	0.00017	0.00177	CcSEcCtD
Carvedilol—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00017	0.00177	CcSEcCtD
Carvedilol—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000168	0.00175	CcSEcCtD
Carvedilol—Discomfort—Simvastatin—atherosclerosis	0.000168	0.00175	CcSEcCtD
Carvedilol—Angioedema—Niacin—atherosclerosis	0.000168	0.00175	CcSEcCtD
Carvedilol—Ill-defined disorder—Pravastatin—atherosclerosis	0.000168	0.00175	CcSEcCtD
Carvedilol—ADRA1A—adipose tissue—atherosclerosis	0.000168	0.00243	CbGeAlD
Carvedilol—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000168	0.00175	CcSEcCtD
Carvedilol—Anaemia—Pravastatin—atherosclerosis	0.000167	0.00174	CcSEcCtD
Carvedilol—Anorexia—Lovastatin—atherosclerosis	0.000166	0.00173	CcSEcCtD
Carvedilol—Skin disorder—Ezetimibe—atherosclerosis	0.000166	0.00173	CcSEcCtD
Carvedilol—ADRA2A—connective tissue—atherosclerosis	0.000166	0.00241	CbGeAlD
Carvedilol—Angioedema—Pravastatin—atherosclerosis	0.000165	0.00172	CcSEcCtD
Carvedilol—Vertigo—Niacin—atherosclerosis	0.000165	0.00172	CcSEcCtD
Carvedilol—Syncope—Niacin—atherosclerosis	0.000165	0.00172	CcSEcCtD
Carvedilol—Confusional state—Simvastatin—atherosclerosis	0.000165	0.00171	CcSEcCtD
Carvedilol—Leukopenia—Niacin—atherosclerosis	0.000164	0.00171	CcSEcCtD
Carvedilol—Urticaria—Rosuvastatin—atherosclerosis	0.000164	0.0017	CcSEcCtD
Carvedilol—Oedema—Simvastatin—atherosclerosis	0.000163	0.0017	CcSEcCtD
Carvedilol—Anaphylactic shock—Simvastatin—atherosclerosis	0.000163	0.0017	CcSEcCtD
Carvedilol—Malaise—Pravastatin—atherosclerosis	0.000163	0.0017	CcSEcCtD
Carvedilol—Abdominal pain—Rosuvastatin—atherosclerosis	0.000163	0.0017	CcSEcCtD
Carvedilol—Vertigo—Pravastatin—atherosclerosis	0.000163	0.00169	CcSEcCtD
Carvedilol—Palpitations—Niacin—atherosclerosis	0.000162	0.00169	CcSEcCtD
Carvedilol—Infection—Simvastatin—atherosclerosis	0.000162	0.00169	CcSEcCtD
Carvedilol—Leukopenia—Pravastatin—atherosclerosis	0.000162	0.00169	CcSEcCtD
Carvedilol—Loss of consciousness—Niacin—atherosclerosis	0.000162	0.00168	CcSEcCtD
Carvedilol—Cough—Niacin—atherosclerosis	0.00016	0.00167	CcSEcCtD
Carvedilol—ADRA2C—adipose tissue—atherosclerosis	0.00016	0.00231	CbGeAlD
Carvedilol—Thrombocytopenia—Simvastatin—atherosclerosis	0.00016	0.00166	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000159	0.00166	CcSEcCtD
Carvedilol—Insomnia—Lovastatin—atherosclerosis	0.000158	0.00164	CcSEcCtD
Carvedilol—Cough—Pravastatin—atherosclerosis	0.000158	0.00164	CcSEcCtD
Carvedilol—Paraesthesia—Lovastatin—atherosclerosis	0.000157	0.00163	CcSEcCtD
Carvedilol—PTGS1—connective tissue—atherosclerosis	0.000157	0.00227	CbGeAlD
Carvedilol—Myalgia—Niacin—atherosclerosis	0.000156	0.00163	CcSEcCtD
Carvedilol—Arthralgia—Niacin—atherosclerosis	0.000156	0.00163	CcSEcCtD
Carvedilol—Hypertension—Pravastatin—atherosclerosis	0.000156	0.00163	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000156	0.00162	CcSEcCtD
Carvedilol—Anorexia—Simvastatin—atherosclerosis	0.000156	0.00162	CcSEcCtD
Carvedilol—Dyspnoea—Lovastatin—atherosclerosis	0.000156	0.00162	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000155	0.00162	CcSEcCtD
Carvedilol—Insomnia—Ezetimibe—atherosclerosis	0.000155	0.00161	CcSEcCtD
Carvedilol—Chest pain—Pravastatin—atherosclerosis	0.000154	0.0016	CcSEcCtD
Carvedilol—Myalgia—Pravastatin—atherosclerosis	0.000154	0.0016	CcSEcCtD
Carvedilol—Arthralgia—Pravastatin—atherosclerosis	0.000154	0.0016	CcSEcCtD
Carvedilol—Paraesthesia—Ezetimibe—atherosclerosis	0.000154	0.0016	CcSEcCtD
Carvedilol—Dyspepsia—Lovastatin—atherosclerosis	0.000154	0.0016	CcSEcCtD
Carvedilol—Dry mouth—Niacin—atherosclerosis	0.000153	0.00159	CcSEcCtD
Carvedilol—Dyspnoea—Ezetimibe—atherosclerosis	0.000153	0.00159	CcSEcCtD
Carvedilol—Discomfort—Pravastatin—atherosclerosis	0.000152	0.00158	CcSEcCtD
Carvedilol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000152	0.00158	CcSEcCtD
Carvedilol—Decreased appetite—Lovastatin—atherosclerosis	0.000152	0.00158	CcSEcCtD
Carvedilol—Dyspepsia—Ezetimibe—atherosclerosis	0.000151	0.00157	CcSEcCtD
Carvedilol—Fatigue—Lovastatin—atherosclerosis	0.000151	0.00157	CcSEcCtD
Carvedilol—Oedema—Niacin—atherosclerosis	0.00015	0.00156	CcSEcCtD
Carvedilol—Anaphylactic shock—Niacin—atherosclerosis	0.00015	0.00156	CcSEcCtD
Carvedilol—CYP2C9—cardiovascular system—atherosclerosis	0.000149	0.00216	CbGeAlD
Carvedilol—Constipation—Lovastatin—atherosclerosis	0.000149	0.00155	CcSEcCtD
Carvedilol—Pain—Lovastatin—atherosclerosis	0.000149	0.00155	CcSEcCtD
Carvedilol—Confusional state—Pravastatin—atherosclerosis	0.000149	0.00155	CcSEcCtD
Carvedilol—Decreased appetite—Ezetimibe—atherosclerosis	0.000149	0.00155	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000149	0.00155	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000148	0.00154	CcSEcCtD
Carvedilol—Asthenia—Rosuvastatin—atherosclerosis	0.000148	0.00154	CcSEcCtD
Carvedilol—Insomnia—Simvastatin—atherosclerosis	0.000148	0.00154	CcSEcCtD
Carvedilol—Oedema—Pravastatin—atherosclerosis	0.000148	0.00154	CcSEcCtD
Carvedilol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000148	0.00154	CcSEcCtD
Carvedilol—Fatigue—Ezetimibe—atherosclerosis	0.000148	0.00154	CcSEcCtD
Carvedilol—Shock—Niacin—atherosclerosis	0.000148	0.00154	CcSEcCtD
Carvedilol—Infection—Pravastatin—atherosclerosis	0.000147	0.00153	CcSEcCtD
Carvedilol—Paraesthesia—Simvastatin—atherosclerosis	0.000147	0.00153	CcSEcCtD
Carvedilol—Constipation—Ezetimibe—atherosclerosis	0.000146	0.00152	CcSEcCtD
Carvedilol—Pain—Ezetimibe—atherosclerosis	0.000146	0.00152	CcSEcCtD
Carvedilol—Tachycardia—Niacin—atherosclerosis	0.000146	0.00152	CcSEcCtD
Carvedilol—Pruritus—Rosuvastatin—atherosclerosis	0.000146	0.00152	CcSEcCtD
Carvedilol—Skin disorder—Niacin—atherosclerosis	0.000146	0.00152	CcSEcCtD
Carvedilol—Dyspnoea—Simvastatin—atherosclerosis	0.000146	0.00152	CcSEcCtD
Carvedilol—Hyperhidrosis—Niacin—atherosclerosis	0.000145	0.00151	CcSEcCtD
Carvedilol—Thrombocytopenia—Pravastatin—atherosclerosis	0.000145	0.0015	CcSEcCtD
Carvedilol—Feeling abnormal—Lovastatin—atherosclerosis	0.000144	0.0015	CcSEcCtD
Carvedilol—Dyspepsia—Simvastatin—atherosclerosis	0.000144	0.0015	CcSEcCtD
Carvedilol—Anorexia—Niacin—atherosclerosis	0.000143	0.00149	CcSEcCtD
Carvedilol—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000143	0.00149	CcSEcCtD
Carvedilol—Hyperhidrosis—Pravastatin—atherosclerosis	0.000143	0.00149	CcSEcCtD
Carvedilol—Decreased appetite—Simvastatin—atherosclerosis	0.000142	0.00148	CcSEcCtD
Carvedilol—CYP2E1—cardiovascular system—atherosclerosis	0.000142	0.00205	CbGeAlD
Carvedilol—Feeling abnormal—Ezetimibe—atherosclerosis	0.000141	0.00147	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000141	0.00147	CcSEcCtD
Carvedilol—Diarrhoea—Rosuvastatin—atherosclerosis	0.000141	0.00147	CcSEcCtD
Carvedilol—Fatigue—Simvastatin—atherosclerosis	0.000141	0.00147	CcSEcCtD
Carvedilol—Anorexia—Pravastatin—atherosclerosis	0.000141	0.00147	CcSEcCtD
Carvedilol—Hypotension—Niacin—atherosclerosis	0.00014	0.00146	CcSEcCtD
Carvedilol—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00014	0.00146	CcSEcCtD
Carvedilol—Constipation—Simvastatin—atherosclerosis	0.00014	0.00145	CcSEcCtD
Carvedilol—Pain—Simvastatin—atherosclerosis	0.00014	0.00145	CcSEcCtD
Carvedilol—Urticaria—Lovastatin—atherosclerosis	0.000139	0.00144	CcSEcCtD
Carvedilol—Abdominal pain—Lovastatin—atherosclerosis	0.000138	0.00144	CcSEcCtD
Carvedilol—Body temperature increased—Lovastatin—atherosclerosis	0.000138	0.00144	CcSEcCtD
Carvedilol—CYP1A1—adipose tissue—atherosclerosis	0.000137	0.00198	CbGeAlD
Carvedilol—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000137	0.00142	CcSEcCtD
Carvedilol—PTGS1—cardiovascular system—atherosclerosis	0.000136	0.00197	CbGeAlD
Carvedilol—Dizziness—Rosuvastatin—atherosclerosis	0.000136	0.00142	CcSEcCtD
Carvedilol—Urticaria—Ezetimibe—atherosclerosis	0.000136	0.00142	CcSEcCtD
Carvedilol—Insomnia—Niacin—atherosclerosis	0.000136	0.00141	CcSEcCtD
Carvedilol—Body temperature increased—Ezetimibe—atherosclerosis	0.000135	0.00141	CcSEcCtD
Carvedilol—Abdominal pain—Ezetimibe—atherosclerosis	0.000135	0.00141	CcSEcCtD
Carvedilol—Paraesthesia—Niacin—atherosclerosis	0.000135	0.0014	CcSEcCtD
Carvedilol—Feeling abnormal—Simvastatin—atherosclerosis	0.000135	0.0014	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000135	0.0014	CcSEcCtD
Carvedilol—Dyspnoea—Niacin—atherosclerosis	0.000134	0.00139	CcSEcCtD
Carvedilol—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000134	0.00139	CcSEcCtD
Carvedilol—Insomnia—Pravastatin—atherosclerosis	0.000134	0.00139	CcSEcCtD
Carvedilol—Somnolence—Niacin—atherosclerosis	0.000133	0.00139	CcSEcCtD
Carvedilol—Paraesthesia—Pravastatin—atherosclerosis	0.000133	0.00138	CcSEcCtD
Carvedilol—Dyspepsia—Niacin—atherosclerosis	0.000132	0.00137	CcSEcCtD
Carvedilol—Dyspnoea—Pravastatin—atherosclerosis	0.000132	0.00137	CcSEcCtD
Carvedilol—Decreased appetite—Niacin—atherosclerosis	0.00013	0.00136	CcSEcCtD
Carvedilol—Dyspepsia—Pravastatin—atherosclerosis	0.00013	0.00135	CcSEcCtD
Carvedilol—Rash—Rosuvastatin—atherosclerosis	0.00013	0.00135	CcSEcCtD
Carvedilol—Dermatitis—Rosuvastatin—atherosclerosis	0.00013	0.00135	CcSEcCtD
Carvedilol—Urticaria—Simvastatin—atherosclerosis	0.00013	0.00135	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Niacin—atherosclerosis	0.000129	0.00135	CcSEcCtD
Carvedilol—Body temperature increased—Simvastatin—atherosclerosis	0.000129	0.00134	CcSEcCtD
Carvedilol—Abdominal pain—Simvastatin—atherosclerosis	0.000129	0.00134	CcSEcCtD
Carvedilol—Headache—Rosuvastatin—atherosclerosis	0.000129	0.00134	CcSEcCtD
Carvedilol—Hypersensitivity—Lovastatin—atherosclerosis	0.000129	0.00134	CcSEcCtD
Carvedilol—Decreased appetite—Pravastatin—atherosclerosis	0.000128	0.00134	CcSEcCtD
Carvedilol—Pain—Niacin—atherosclerosis	0.000128	0.00133	CcSEcCtD
Carvedilol—ADRA2A—adipose tissue—atherosclerosis	0.000128	0.00185	CbGeAlD
Carvedilol—Fatigue—Pravastatin—atherosclerosis	0.000127	0.00133	CcSEcCtD
Carvedilol—Constipation—Pravastatin—atherosclerosis	0.000126	0.00131	CcSEcCtD
Carvedilol—Pain—Pravastatin—atherosclerosis	0.000126	0.00131	CcSEcCtD
Carvedilol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000126	0.00131	CcSEcCtD
Carvedilol—Asthenia—Lovastatin—atherosclerosis	0.000125	0.0013	CcSEcCtD
Carvedilol—Pruritus—Lovastatin—atherosclerosis	0.000124	0.00129	CcSEcCtD
Carvedilol—Asthenia—Ezetimibe—atherosclerosis	0.000123	0.00128	CcSEcCtD
Carvedilol—Gastrointestinal pain—Niacin—atherosclerosis	0.000123	0.00128	CcSEcCtD
Carvedilol—Nausea—Rosuvastatin—atherosclerosis	0.000122	0.00127	CcSEcCtD
Carvedilol—Feeling abnormal—Pravastatin—atherosclerosis	0.000122	0.00127	CcSEcCtD
Carvedilol—Pruritus—Ezetimibe—atherosclerosis	0.000121	0.00126	CcSEcCtD
Carvedilol—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000121	0.00126	CcSEcCtD
Carvedilol—Hypersensitivity—Simvastatin—atherosclerosis	0.00012	0.00125	CcSEcCtD
Carvedilol—PTGS1—adipose tissue—atherosclerosis	0.00012	0.00174	CbGeAlD
Carvedilol—Diarrhoea—Lovastatin—atherosclerosis	0.000119	0.00124	CcSEcCtD
Carvedilol—Urticaria—Niacin—atherosclerosis	0.000119	0.00124	CcSEcCtD
Carvedilol—Body temperature increased—Niacin—atherosclerosis	0.000119	0.00123	CcSEcCtD
Carvedilol—Abdominal pain—Niacin—atherosclerosis	0.000119	0.00123	CcSEcCtD
Carvedilol—ADRA1A—liver—atherosclerosis	0.000118	0.0017	CbGeAlD
Carvedilol—Urticaria—Pravastatin—atherosclerosis	0.000117	0.00122	CcSEcCtD
Carvedilol—Asthenia—Simvastatin—atherosclerosis	0.000117	0.00122	CcSEcCtD
Carvedilol—Diarrhoea—Ezetimibe—atherosclerosis	0.000117	0.00122	CcSEcCtD
Carvedilol—Body temperature increased—Pravastatin—atherosclerosis	0.000117	0.00122	CcSEcCtD
Carvedilol—Abdominal pain—Pravastatin—atherosclerosis	0.000117	0.00122	CcSEcCtD
Carvedilol—Pruritus—Simvastatin—atherosclerosis	0.000116	0.0012	CcSEcCtD
Carvedilol—Dizziness—Lovastatin—atherosclerosis	0.000115	0.0012	CcSEcCtD
Carvedilol—Dizziness—Ezetimibe—atherosclerosis	0.000113	0.00118	CcSEcCtD
Carvedilol—ADRA2C—liver—atherosclerosis	0.000112	0.00162	CbGeAlD
Carvedilol—Diarrhoea—Simvastatin—atherosclerosis	0.000112	0.00116	CcSEcCtD
Carvedilol—Vomiting—Lovastatin—atherosclerosis	0.000111	0.00116	CcSEcCtD
Carvedilol—Hypersensitivity—Niacin—atherosclerosis	0.00011	0.00115	CcSEcCtD
Carvedilol—Rash—Lovastatin—atherosclerosis	0.00011	0.00115	CcSEcCtD
Carvedilol—Dermatitis—Lovastatin—atherosclerosis	0.00011	0.00114	CcSEcCtD
Carvedilol—Headache—Lovastatin—atherosclerosis	0.000109	0.00114	CcSEcCtD
Carvedilol—Vomiting—Ezetimibe—atherosclerosis	0.000109	0.00113	CcSEcCtD
Carvedilol—Hypersensitivity—Pravastatin—atherosclerosis	0.000109	0.00113	CcSEcCtD
Carvedilol—Dizziness—Simvastatin—atherosclerosis	0.000108	0.00112	CcSEcCtD
Carvedilol—Rash—Ezetimibe—atherosclerosis	0.000108	0.00112	CcSEcCtD
Carvedilol—Dermatitis—Ezetimibe—atherosclerosis	0.000108	0.00112	CcSEcCtD
Carvedilol—Asthenia—Niacin—atherosclerosis	0.000108	0.00112	CcSEcCtD
Carvedilol—Headache—Ezetimibe—atherosclerosis	0.000107	0.00112	CcSEcCtD
Carvedilol—Pruritus—Niacin—atherosclerosis	0.000106	0.0011	CcSEcCtD
Carvedilol—Asthenia—Pravastatin—atherosclerosis	0.000106	0.0011	CcSEcCtD
Carvedilol—Pruritus—Pravastatin—atherosclerosis	0.000104	0.00109	CcSEcCtD
Carvedilol—Vomiting—Simvastatin—atherosclerosis	0.000104	0.00108	CcSEcCtD
Carvedilol—Nausea—Lovastatin—atherosclerosis	0.000104	0.00108	CcSEcCtD
Carvedilol—Rash—Simvastatin—atherosclerosis	0.000103	0.00107	CcSEcCtD
Carvedilol—Dermatitis—Simvastatin—atherosclerosis	0.000103	0.00107	CcSEcCtD
Carvedilol—Diarrhoea—Niacin—atherosclerosis	0.000103	0.00107	CcSEcCtD
Carvedilol—Headache—Simvastatin—atherosclerosis	0.000102	0.00107	CcSEcCtD
Carvedilol—Nausea—Ezetimibe—atherosclerosis	0.000102	0.00106	CcSEcCtD
Carvedilol—Diarrhoea—Pravastatin—atherosclerosis	0.000101	0.00105	CcSEcCtD
Carvedilol—Dizziness—Niacin—atherosclerosis	9.92e-05	0.00103	CcSEcCtD
Carvedilol—Dizziness—Pravastatin—atherosclerosis	9.77e-05	0.00102	CcSEcCtD
Carvedilol—CYP1A2—liver—atherosclerosis	9.73e-05	0.00141	CbGeAlD
Carvedilol—Nausea—Simvastatin—atherosclerosis	9.7e-05	0.00101	CcSEcCtD
Carvedilol—CYP1A1—liver—atherosclerosis	9.6e-05	0.00139	CbGeAlD
Carvedilol—Vomiting—Niacin—atherosclerosis	9.54e-05	0.000993	CcSEcCtD
Carvedilol—Rash—Niacin—atherosclerosis	9.46e-05	0.000984	CcSEcCtD
Carvedilol—Dermatitis—Niacin—atherosclerosis	9.45e-05	0.000983	CcSEcCtD
Carvedilol—Headache—Niacin—atherosclerosis	9.4e-05	0.000978	CcSEcCtD
Carvedilol—Vomiting—Pravastatin—atherosclerosis	9.39e-05	0.000977	CcSEcCtD
Carvedilol—Rash—Pravastatin—atherosclerosis	9.31e-05	0.000969	CcSEcCtD
Carvedilol—Dermatitis—Pravastatin—atherosclerosis	9.3e-05	0.000968	CcSEcCtD
Carvedilol—Headache—Pravastatin—atherosclerosis	9.25e-05	0.000963	CcSEcCtD
Carvedilol—CYP2C9—liver—atherosclerosis	9.24e-05	0.00134	CbGeAlD
Carvedilol—Nausea—Niacin—atherosclerosis	8.91e-05	0.000927	CcSEcCtD
Carvedilol—Nausea—Pravastatin—atherosclerosis	8.77e-05	0.000913	CcSEcCtD
Carvedilol—CYP2E1—liver—atherosclerosis	8.76e-05	0.00127	CbGeAlD
Carvedilol—ABCB1—cardiovascular system—atherosclerosis	8.06e-05	0.00117	CbGeAlD
Carvedilol—ABCB1—adipose tissue—atherosclerosis	7.11e-05	0.00103	CbGeAlD
Carvedilol—CYP3A4—liver—atherosclerosis	7.05e-05	0.00102	CbGeAlD
Carvedilol—CYP2D6—liver—atherosclerosis	6.93e-05	0.001	CbGeAlD
Carvedilol—ABCB1—liver—atherosclerosis	4.99e-05	0.000721	CbGeAlD
Carvedilol—ADRB1—Signaling Pathways—NOS3—atherosclerosis	1.65e-06	1.53e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—LIPC—atherosclerosis	1.65e-06	1.53e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CG—atherosclerosis	1.64e-06	1.53e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	1.64e-06	1.53e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—APOC3—atherosclerosis	1.64e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	1.63e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOS3—atherosclerosis	1.63e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—LPL—atherosclerosis	1.63e-06	1.52e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—LDLR—atherosclerosis	1.63e-06	1.52e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOS3—atherosclerosis	1.61e-06	1.5e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—APOB—atherosclerosis	1.61e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	1.61e-06	1.5e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCL8—atherosclerosis	1.6e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SERPINE1—atherosclerosis	1.6e-06	1.49e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—APOB—atherosclerosis	1.6e-06	1.49e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GPX1—atherosclerosis	1.59e-06	1.48e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CETP—atherosclerosis	1.59e-06	1.48e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PPARG—atherosclerosis	1.58e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	1.58e-06	1.47e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	1.57e-06	1.46e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.57e-06	1.46e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—F2—atherosclerosis	1.56e-06	1.45e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GSTM1—atherosclerosis	1.55e-06	1.45e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—INS—atherosclerosis	1.55e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CD36—atherosclerosis	1.55e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—AKT1—atherosclerosis	1.55e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ALB—atherosclerosis	1.55e-06	1.44e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CG—atherosclerosis	1.54e-06	1.44e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	1.54e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—LPL—atherosclerosis	1.54e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL6—atherosclerosis	1.52e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	1.52e-06	1.42e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—LPL—atherosclerosis	1.52e-06	1.42e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.52e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—INS—atherosclerosis	1.52e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	1.5e-06	1.4e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GPX1—atherosclerosis	1.5e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	1.49e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	1.49e-06	1.39e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PPARG—atherosclerosis	1.49e-06	1.39e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GPX1—atherosclerosis	1.49e-06	1.38e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—NOS3—atherosclerosis	1.48e-06	1.38e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	1.47e-06	1.37e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—MTHFR—atherosclerosis	1.47e-06	1.37e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—INS—atherosclerosis	1.46e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	1.46e-06	1.36e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CD36—atherosclerosis	1.46e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—atherosclerosis	1.45e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	1.45e-06	1.35e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CD36—atherosclerosis	1.45e-06	1.35e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARA—atherosclerosis	1.44e-06	1.34e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.44e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NFKB1—atherosclerosis	1.43e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	1.43e-06	1.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	1.43e-06	1.33e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.42e-06	1.33e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ALB—atherosclerosis	1.42e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—INS—atherosclerosis	1.41e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	1.41e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	1.41e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	1.41e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	1.4e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	1.4e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AGT—atherosclerosis	1.39e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6—atherosclerosis	1.39e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	1.39e-06	1.29e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.38e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—atherosclerosis	1.38e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	1.38e-06	1.29e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—atherosclerosis	1.38e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	1.38e-06	1.28e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—MTHFR—atherosclerosis	1.37e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—APOE—atherosclerosis	1.37e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	1.37e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—APOB—atherosclerosis	1.36e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—NOS3—atherosclerosis	1.36e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—atherosclerosis	1.36e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARA—atherosclerosis	1.36e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—atherosclerosis	1.35e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CAV1—atherosclerosis	1.35e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	1.35e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—APOA1—atherosclerosis	1.35e-06	1.26e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARA—atherosclerosis	1.35e-06	1.25e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ALB—atherosclerosis	1.34e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	1.33e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	1.33e-06	1.24e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.33e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—atherosclerosis	1.32e-06	1.23e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AGT—atherosclerosis	1.31e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	1.31e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	1.31e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	1.31e-06	1.22e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AGT—atherosclerosis	1.3e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	1.3e-06	1.21e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—LPL—atherosclerosis	1.3e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.3e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	1.3e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—atherosclerosis	1.29e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	1.29e-06	1.2e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—APOE—atherosclerosis	1.29e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	1.29e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	1.29e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	1.28e-06	1.2e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—NOS3—atherosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—APOE—atherosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CAV1—atherosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AKT1—atherosclerosis	1.28e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	1.27e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—APOA1—atherosclerosis	1.27e-06	1.19e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AKT1—atherosclerosis	1.27e-06	1.19e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GPX1—atherosclerosis	1.27e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	1.27e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	1.27e-06	1.18e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CAV1—atherosclerosis	1.26e-06	1.18e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—APOA1—atherosclerosis	1.26e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	1.26e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	1.25e-06	1.17e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—atherosclerosis	1.24e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.24e-06	1.15e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CD36—atherosclerosis	1.24e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.23e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	1.23e-06	1.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	1.22e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	1.21e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	1.2e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	1.2e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.19e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PPARG—atherosclerosis	1.19e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	1.19e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	1.19e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	1.19e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	1.18e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	1.18e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STAT3—atherosclerosis	1.17e-06	1.09e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—atherosclerosis	1.17e-06	1.09e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.17e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.17e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—INS—atherosclerosis	1.17e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.17e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	1.16e-06	1.08e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.16e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	1.16e-06	1.08e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CG—atherosclerosis	1.15e-06	1.07e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARA—atherosclerosis	1.15e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STAT3—atherosclerosis	1.15e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	1.14e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	1.12e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	1.12e-06	1.05e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PPARG—atherosclerosis	1.12e-06	1.05e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AGT—atherosclerosis	1.11e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	1.11e-06	1.04e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PPARG—atherosclerosis	1.11e-06	1.04e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—INS—atherosclerosis	1.1e-06	1.03e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.1e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.1e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	1.1e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	1.1e-06	1.02e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—APOE—atherosclerosis	1.09e-06	1.02e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—INS—atherosclerosis	1.09e-06	1.02e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	1.09e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	1.09e-06	1.01e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CAV1—atherosclerosis	1.08e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	1.08e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	1.08e-06	1.01e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—APOA1—atherosclerosis	1.08e-06	1e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ALB—atherosclerosis	1.07e-06	9.97e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	1.07e-06	9.97e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	1.07e-06	9.96e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	1.07e-06	9.93e-06	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.06e-06	9.89e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	1.06e-06	9.86e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—APOB—atherosclerosis	1.05e-06	9.8e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.04e-06	9.73e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	1.04e-06	9.69e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	1.04e-06	9.68e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	1.04e-06	9.66e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—NOS3—atherosclerosis	1.02e-06	9.54e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.02e-06	9.54e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	1.02e-06	9.53e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ALB—atherosclerosis	1.01e-06	9.4e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	1.01e-06	9.39e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—LPL—atherosclerosis	1e-06	9.36e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ALB—atherosclerosis	1e-06	9.32e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	9.93e-07	9.26e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	9.92e-07	9.24e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CG—atherosclerosis	9.85e-07	9.17e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	9.83e-07	9.16e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GPX1—atherosclerosis	9.8e-07	9.13e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	9.66e-07	9e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NOS3—atherosclerosis	9.65e-07	8.99e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	9.63e-07	8.98e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	9.6e-07	8.95e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NOS3—atherosclerosis	9.56e-07	8.91e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CD36—atherosclerosis	9.54e-07	8.89e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	9.51e-07	8.86e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PPARG—atherosclerosis	9.5e-07	8.85e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—atherosclerosis	9.36e-07	8.73e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—INS—atherosclerosis	9.32e-07	8.68e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	9.08e-07	8.46e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—MTHFR—atherosclerosis	9.04e-07	8.43e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—atherosclerosis	9.01e-07	8.39e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	8.92e-07	8.31e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARA—atherosclerosis	8.87e-07	8.27e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	8.83e-07	8.23e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—atherosclerosis	8.82e-07	8.22e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	8.81e-07	8.21e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—atherosclerosis	8.75e-07	8.15e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AGT—atherosclerosis	8.59e-07	8.01e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ALB—atherosclerosis	8.54e-07	7.96e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	8.44e-07	7.86e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—APOE—atherosclerosis	8.42e-07	7.85e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AKT1—atherosclerosis	8.38e-07	7.81e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AKT1—atherosclerosis	8.36e-07	7.79e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CAV1—atherosclerosis	8.34e-07	7.77e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—APOA1—atherosclerosis	8.32e-07	7.76e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	8.31e-07	7.74e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—atherosclerosis	8.21e-07	7.65e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	8.19e-07	7.63e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NOS3—atherosclerosis	8.17e-07	7.62e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—atherosclerosis	8.13e-07	7.58e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—atherosclerosis	8.03e-07	7.48e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CG—atherosclerosis	7.6e-07	7.08e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—atherosclerosis	7.59e-07	7.08e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AKT1—atherosclerosis	7.57e-07	7.05e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	7.5e-07	6.99e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—atherosclerosis	7.48e-07	6.97e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—atherosclerosis	7.47e-07	6.97e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AKT1—atherosclerosis	7.41e-07	6.9e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PPARG—atherosclerosis	7.33e-07	6.83e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—INS—atherosclerosis	7.19e-07	6.7e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	7.01e-07	6.53e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	6.9e-07	6.43e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AKT1—atherosclerosis	6.81e-07	6.34e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—atherosclerosis	6.64e-07	6.19e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ALB—atherosclerosis	6.59e-07	6.14e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NOS3—atherosclerosis	6.31e-07	5.88e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AKT1—atherosclerosis	6.25e-07	5.82e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—atherosclerosis	6.17e-07	5.75e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	6.13e-07	5.71e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AKT1—atherosclerosis	5.89e-07	5.49e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.77e-07	5.38e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	5.69e-07	5.3e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AKT1—atherosclerosis	4.71e-07	4.39e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AKT1—atherosclerosis	4.43e-07	4.13e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AKT1—atherosclerosis	4.4e-07	4.1e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AKT1—atherosclerosis	3.76e-07	3.5e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AKT1—atherosclerosis	2.9e-07	2.7e-06	CbGpPWpGaD
